ANIP - ANI Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ANIP is currently covered by 4 analysts with an average price target of $84.14. This is a potential upside of $17.16 (25.62%) from yesterday's end of day stock price of $66.98.

ANI Pharmaceuticals's activity chart (see below) currently has 60 price targets and 64 ratings on display. The stock rating distribution of ANIP is 92% BUY and 8% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 78.71% with an average time for these price targets to be met of 338.13 days.

Highest price target for ANIP is $94, Lowest price target is $62, average price target is $81.25.

Most recent stock forecast was given by VAMIL DIVAN from GUGGENHEIM on 12-May-2025. First documented stock forecast 15-Dec-2014.

Currently out of the existing stock ratings of ANIP, 23 are a BUY (92%), 2 are a HOLD (8%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$86

$20.44 (31.18%)

$86

1 months 12 days ago
(12-May-2025)

6/10 (60%)

$23.7 (38.04%)

343

Buy

$94

$28.44 (43.38%)

$94

3 months 7 days ago
(17-Mar-2025)

4/13 (30.77%)

$29.65 (46.08%)

148

Hold

$62

$-3.56 (-5.43%)

$60

8 months 2 days ago
(22-Oct-2024)

8/9 (88.89%)

$1.92 (3.20%)

396

Buy

$83

$17.44 (26.60%)

$49

9 months 6 days ago
(18-Sep-2024)

10/12 (83.33%)

$21.95 (35.95%)

474

Hold

$42

$-23.56 (-35.94%)

$40

2 years 1 months 16 days ago
(08-May-2023)

2/3 (66.67%)

$-0.58 (-1.36%)

274

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ANIP (ANI Pharmaceuticals) average time for price targets to be met?

On average it took 338.13 days on average for the stock forecasts to be realized with a an average price target met ratio 78.71

Which analyst has the current highest performing score on ANIP (ANI Pharmaceuticals) with a proven track record?

LOUISE CHEN

Which analyst has the current lower performing score on ANIP (ANI Pharmaceuticals) with a proven track record?

BRANDON FOLKES

Which analyst has the most public recommendations on ANIP (ANI Pharmaceuticals)?

Louise Chen works at SCOTIABANK and has 9 price targets and 5 ratings on ANIP

Which analyst is the currently most bullish on ANIP (ANI Pharmaceuticals)?

Oren Livnat with highest potential upside - $28.44

Which analyst is the currently most reserved on ANIP (ANI Pharmaceuticals)?

Brandon Folkes with lowest potential downside - -$23.56

ANI Pharmaceuticals in the News

Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported first-quarter adjusted earnings of $1.70 per share on Friday, up from $1.21 a year ago, beating the consensus of $1.38 per share. The company reported sales of $197.12 million, up 43.4% year over year, beating the consensus of $180.68 million. On an organic basis, excluding the acquisition of Alimera, total...

Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics

ANI Pharmaceuticals (ANIP) reported $197.12 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 43.4%. EPS of $1.70 for the same period compares to $1.21 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $179.45 million, representing a surprise of +9.85%. The company delivered an EPS...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?